Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

As an early funder of Capricor Therapeutics, we are pleased to share that they will be continuing their Phase 3 Trial of CAP-1002—a cell and exosome-based therapeutic–in Duchenne.  An independent Data Safety Monitoring Board (DSMB) recently conducted an interim futility analysis of the study, and issued a favorable recommendation to continue.  

Topline data on the first cohort is expected at the end of 2024;  a second cohort is currently recruiting.

Read the full PRESS RELEASE HERE